Memo - Magazine of European Medical Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Essential news for clinical practice —thyroid cancer
SummaryEstablished systemic treatment options for advanced thyroid cancer include the multityrosine kinase inhibitors lenvatinib and sorafenib for radioactive iodine refractory differentiated thyroid cancer (DTC) and vandetanib and cabozantinib for medullary thyroid cancer (MTC). Recently, the COSMIC-311  study resulted in approval of cabozantinib for DTC with progression upon lenvatinib and/or sorafenib; thus, for the first time a specific second-line therapy has been defined for these patients. In addition, the therapeutic landscape of thyroid cancer has been expanded by targeted therapies based on molecular tumor prof...
Source: Memo - Magazine of European Medical Oncology - January 10, 2023 Category: Cancer & Oncology Source Type: research

Vaccination against SARS-CoV-2 in adults with a  diagnosis of cancer: a short review
SummaryCompared to individuals without cancer, patients with a  diagnosis of malignancy bear a higher risk of becoming infected with SARS-CoV‑2, suffer more frequently from disease-related complications, and are more likely to die due to coronavirus disease 2019 (COVID-19). Depending on the type of cancer and the treatment received, the immune response to v accination may also be affected in patients with certain types of malignancy. Therefore, there is a need for more specific COVID-19 vaccination recommendations in individuals with a diagnosis of cancer. Furthermore, pre-exposition prophylaxis should be considered ...
Source: Memo - Magazine of European Medical Oncology - January 5, 2023 Category: Cancer & Oncology Source Type: research

Dual immune checkpoint blockade in gastroesophageal tumors: never say never
SummaryImmunotherapy was proven to be effective as first-line treatment for a  subgroup of patients with gastroesophageal tumors and is already established as the standard of care. However, chemotherapy remains the backbone of treatment in both advanced and resectable stages. Dual checkpoint inhibition produces synergistic activation of immune cells and enhanced antitumor ac tivity, and could thus represent an alternative to chemotherapy. So far, there is evidence for the combination strategies of inhibitors of the PD-L1/PD‑1 axis and CTLA4, LAG3 and TIGIT. A combination therapy of nivolumab+ipilimumab has already been...
Source: Memo - Magazine of European Medical Oncology - January 3, 2023 Category: Cancer & Oncology Source Type: research

A GLOBAL CONGRESS DIGEST ON SOLID TUMORS. Report from the ESMO Hybrid Congress , 9th – 13th September 2022
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 21, 2022 Category: Cancer & Oncology Source Type: research

Theranostics in prostate cancer
SummaryThis review summarizes current evidence of “theranostics” for patients with prostate cancer. Prostate-specific membrane antigen (PSMA) is a glycoprotein which can be labeled with positron-emitting tomographic (PET) tracers like fluorine-18, gallium-68, or copper-64 and can be labeled with beta emitters like lutetium-177 to treat patient s with metastatic castration-resistant prostate cancer (mCRPC). PSMA PET/CT has been shown to be superior to computer tomography (CT) and bone scintigraphy in accuracy, sensitivity, and specificity in the evaluation of metastatic tumor sites and may change treatment management. ...
Source: Memo - Magazine of European Medical Oncology - December 19, 2022 Category: Cancer & Oncology Source Type: research

A GLOBAL CONGRESS DIGEST ON LUNG CANCER. Report from the ESMO Hybrid Congress , 9th – 13th September 2022
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 14, 2022 Category: Cancer & Oncology Source Type: research

Hodgkin lymphoma —how much therapy do we need?
SummaryOver the past few decades, cure rates for Hodgkin ’s lymphoma (HL) have consistently improved with advances in chemotherapy and radiation treatment. However, these therapies—whilst highly effective—may result in significant long-term toxicity with patients being at an increased risk of secondary malignancies, cardiopulmonary long-term toxicit y, lower fertility rates and impaired quality of life. Consequently, efforts have been made to reduce side effects while maintaining good response rates. Various studies have examined the possibility of treatment reduction, either through omitting treatment cycles, substa...
Source: Memo - Magazine of European Medical Oncology - December 12, 2022 Category: Cancer & Oncology Source Type: research

Biomarkers and translational research approaches in breast cancer —an update
SummaryDiagnosis and decision-making in the treatment of breast cancer patients is vastly dependent on the exploration of biomarkers. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor  2 are long-standing biomarkers, which determine the breast cancer subtype. In current practice, gene expression analyses further define the molecular breast cancer subtype and give additional information on disease characteristics. Prognostic biomarkers provide information regarding recurrence ri sk and survival. Predictive biomarkers, such as programmed cell death ligand 1 expression, are tools for ide...
Source: Memo - Magazine of European Medical Oncology - December 12, 2022 Category: Cancer & Oncology Source Type: research

Hodgkin lymphoma —how much therapy do we need?
SummaryOver the past few decades, cure rates for Hodgkin ’s lymphoma (HL) have consistently improved with advances in chemotherapy and radiation treatment. However, these therapies—whilst highly effective—may result in significant long-term toxicity with patients being at an increased risk of secondary malignancies, cardiopulmonary long-term toxicit y, lower fertility rates and impaired quality of life. Consequently, efforts have been made to reduce side effects while maintaining good response rates. Various studies have examined the possibility of treatment reduction, either through omitting treatment cycles, substa...
Source: Memo - Magazine of European Medical Oncology - December 12, 2022 Category: Cancer & Oncology Source Type: research